Phase Ii Study Of Avelumab Plus Intermittent Axitinib In Previously Untreated Patients With Metastatic Renal Cell Carcinoma (Tide-A Study)

Roberto Iacovelli,Francesco Atzori,Umberto Basso,Melissa Bersanelli, Lucia Bonomi,Sergio Bracarda,Consuelo Buttigliero,Emanuela Fantinel,Fabio Calabro,Vincenzo Emanuele Chiuri,Giuseppe Di Lorenzo,Giuseppe Fornarini,Francesco Massari,Emanuele Naglieri,Cinzia Ortega,Giuseppe Procopio,Michele Milella,Matteo Santoni,Maria Giuseppa Vitale,Paolo Andrea Zucali

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 1|浏览191

暂无评分

摘要

TPS762Background: The combination of avelumab plus axitinib has been recently reported to be superior than sunitinib alone for treatment of previously untreated mRCC patients (Motzer, NEJM 2019). T...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要